ICH M12 Drug Interaction Studies: EMA Targets the Gut Gap
The EMA’s draft guideline extends ICH M12 drug interaction studies to the gut. See what it asks on food effect, gastric pH, and excipients, and how to respond.
Genomic Governance Ensures Equity at the Core of Drug Discovery
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
Next-Generation Sequencing for Cell Line Development in Biologics Manufacturing
Discover how next-generation sequencing in cell line development is improving biologics manufacturing, quality control, and regulatory confidence.
Cold Chain Optimisation by Rethinking Pharma Logistics
See how cold chain optimisation can reduce pharmaceutical logistics costs, emissions, and product risk by modelling uncertainty across storage and distribution.
FDA vs EMA Drug Labelling for Global Medical Safety
We explain the FDA vs EMA drug labelling requirements, regional safety differences, pharmacovigilance updates, and the role of harmonisation in medicine safety.
Making Flexibility Work with Adaptive Clinical Trials
Adaptive clinical trials can improve efficiency, reduce patient burden, and support faster development through structured, evidence-based flexibility.